Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
No Hog - it wasn't needed. Its a funny one.
I do wonder if the company is reaching out to update the shareholders register.
I also wonder if some of these large holders also hold on platforms that have reportable holdings and someone does the math if they are to update.
Whilst the company effectively owes PIs nothing is does have an obligation to ensure that all parties, unless restricted, have access to an even market.
If I was the company, I'd be asking questions of the placees with Allenby. Allenby should be able to account for holdings past and present in this sense.
The trading activity in the run up to the news screams that parties knew and sold expecting to make a quick 25-30% whilst retaining holdings.
For this alone, we should have stuck with E3 instead of dropping the ball and momentum.
If there had been good financial advice and PR advice, this wouldn't have happened. Most of us was expecting E3 to be called up anyhow.
I've asked the company about this too OAPK.
As I've pointed out before, we remain in the dark on what was contained in this placing agreement.
It doesn't create a balanced market. It should effectively mean that all placees are also inside because of this advantage. So for those that traded their positions before this placing, have they also broken the rules?
On Corepath Vs BIO.
My take is that Corepath are still responsible for the testing etc etc. But they was never paying for it. An accredited lab is needed as part of the process to test the entire spectrum of kit needed that will make up the approved FDA marked test.
BIO are paying for the facilitation of this and then marketing it.
We're also assuming that they was involved more than what we got told.
I think the long anticipation added to that.
It's also a bit safer as we aren't then having all the eggs in one basket with Bio-Techne doing everything for us. This could have led to a very low ball buyout. Something we shouldn't want.
Let the company grow significantly before that.
Importantly it's now no costs to us for set up.
Slightly less royalty but it's cashflow. If the test flies, the cashflow grows with the stake in "BIO" with us also benefitting from improvements made to the test along the way.
It's a good first step.
Good post Hogbog 👏
I think what we need is a better understanding of the steps required to get this to market, and understanding of our relationships with the likes of Fair journey, Biotechne and Proteogenix.
A simple process map with a big finger pointing at where we are, to keep it simple wouldn't go a miss.